Render Target: STATIC
Render Timestamp: 2024-11-22T11:17:41.640Z
Commit: 5c4accf06eb7154018ba3f54329c7590f97f534a
XML generation date: 2024-08-01 15:28:18.825
Product last modified at: 2024-05-30T07:02:09.172Z
1% for the planet logo
PDP - Template Name: Polyclonal Antibody
PDP - Template ID: *******59c6464

Delta FosB Antibody #9890

We recommend the following alternatives

Filter:
  • WB
  • IP

Inquiry Info. # 9890

Please see our recommended alternatives.

    Supporting Data

    REACTIVITY H M R Mk
    SENSITIVITY Endogenous
    MW (kDa) 37
    SOURCE Rabbit
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    Species Cross-Reactivity Key:
    • H-Human 
    • M-Mouse 
    • R-Rat 
    • Mk-Monkey 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunoprecipitation 1:50

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    Delta FosB Antibody recognizes endogenous levels of total Delta FosB and Delta2 Delta FosB proteins. This antibody does not cross-react with FosB.

    Species Reactivity:

    Human, Mouse, Rat, Monkey

    Source / Purification

    Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human Delta FosB protein. Antibodies are purified by protein A and peptide affinity chromatography.

    Background

    The Fos family of nuclear oncogenes includes c-Fos, FosB, Fos-related antigen 1 (FRA1), and Fos-related antigen 2 (FRA2) (1). While most Fos proteins exist as a single isoform, the FosB protein exists as two isoforms: full-length FosB and a shorter form, FosB2 (Delta FosB), which lacks the carboxy-terminal 101 amino acids (1-3). The expression of Fos proteins is rapidly and transiently induced by a variety of extracellular stimuli, including growth factors, cytokines, neurotransmitters, polypeptide hormones, and stress. Fos proteins dimerize with Jun proteins (c-Jun, JunB, and JunD) to form Activator Protein-1 (AP-1), a transcription factor that binds to TRE/AP-1 elements and activates transcription. Fos and Jun proteins contain the leucine-zipper motif that mediates dimerization and an adjacent basic domain that binds to DNA. The various Fos/Jun heterodimers differ in their ability to transactivate AP-1 dependent genes. In addition to increased expression, phosphorylation of Fos proteins by Erk kinases in response to extracellular stimuli may further increase transcriptional activity (4-6). Phosphorylation of c-Fos at Ser32 and Thr232 by Erk5 increases protein stability and nuclear localization (5). Phosphorylation of FRA1 at Ser252 and Ser265 by Erk1/2 increases protein stability and leads to overexpression of FRA1 in cancer cells (6). Following growth factor stimulation, expression of FosB and c-Fos in quiescent fibroblasts is immediate, but very short-lived, with protein levels dissipating after several hours (7). FRA1 and FRA2 expression persists longer, and appreciable levels can be detected in asynchronously growing cells (8). Deregulated expression of c-Fos, FosB, or FRA2 can result in neoplastic cellular transformation; however, Delta FosB lacks the ability to transform cells (2,3).

    Delta FosB is encoded by the FosB gene and is produced by alternative splicing. It lacks the 101 C-terminal residues of FosB, a region containing ubiquitination sites, hence conferring higher stability to Delta FosB (9). Delta FosB is induced and accumulates in select brain regions upon chronic drug use (10-12), where it interacts with JunD to form an active long-lasting AP-1 complex (13). This complex has been proposed to represent a molecular switch that helps initiate and maintain the addicted state (14,15).
    1. Tulchinsky, E. (2000) Histol Histopathol 15, 921-8.
    2. Dobrazanski, P. et al. (1991) Mol Cell Biol 11, 5470-8.
    3. Nakabeppu, Y. and Nathans, D. (1991) Cell 64, 751-9.
    4. Rosenberger, S.F. et al. (1999) J Biol Chem 274, 1124-30.
    5. Sasaki, T. et al. (2006) Mol Cell 24, 63-75.
    6. Basbous, J. et al. (2007) Mol Cell Biol 27, 3936-50.
    7. Kovary, K. and Bravo, R. (1991) Mol Cell Biol 11, 2451-9.
    8. Kovary, K. and Bravo, R. (1992) Mol Cell Biol 12, 5015-23.
    9. Carle, T.L. et al. (2007) Eur J Neurosci 25, 3009-3019.
    10. Hope, B.T. et al. (1994) Neuron 13, 1235-1244.
    11. Nye, H.E. et al. (1995) J Pharmacol Exp Ther 275, 1671-1680.
    12. Nye, H.E. and Nestler, E.J. (1996) Mol Pharmacol 49, 636-645.
    13. Chen, J. et al. (1997) J Neurosci 17, 4933-4941.
    14. Nestler, E.J. et al. (2001) Proc Natl Acad Sci USA 98, 11042-11046.
    15. McClung, C.A. et al. (2004) Brain Res Mol Brain Res 132, 146-154.
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.